Composition : Nirmatrelvir 150 mg + Ritonavir 100 mg tablet Description : NIRMACOM is an investigational antiviral therapy medicine with active ingredients Nirmatrelvir 150 MG and Ritonavir 100 MG approved for emergency use. The drug is indicated for treating mild-to-moderate coronavirus disease in adults and pediatric patients (aged >12 years and weight>40 kg) testing positive for SARS-CoV-2 virus, at high risk of progression, including hospitalization or death. Ritonavir is co-administered with Nirmatrelvir as it acts as a pharmacokinetic enhancer resulting in higher systemic concentrations and a longer half-life of Nirmatrelvir, thereby supporting a twice-daily administration regimen. Dose :  The medicine is administered orally with or without food.  Swallow the tablet as a whole. Do not crush, break, or chew it. Uses :  Paxista is approved for emergency use. It is a 5-day treatment that should start as soon as the patient is diagnosed with COVID 19 within five days of symptoms offset. Key Points :  The medicine is not authorized for use longer than five consecutive days.  If the patient skips the dose of Paxista within 8 hours of the time usually taken, the patient should take it within 8 hours, or the skipped dose must be ignored and retained to the regular schedule.  Talk to your doctor if you are taking a combined hormonal contraceptive, have any allergies, liver disease, kidney disease, pregnant, planning to become pregnant, have any serious illness, or breastfeeding mothers.  Females who can become pregnant should use a reliable and effective form of contraception on their doctor’s advice.  Talk to your healthcare provider about your clinical condition after five days.